Yousif Capital Management LLC Trims Stake in Edwards Lifesciences Co. (NYSE:EW)

Yousif Capital Management LLC lessened its holdings in Edwards Lifesciences Co. (NYSE:EW) by 6.7% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 87,633 shares of the medical research company’s stock after selling 6,314 shares during the period. Yousif Capital Management LLC’s holdings in Edwards Lifesciences were worth $6,487,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. FSA Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at about $30,000. Prospera Private Wealth LLC purchased a new stake in Edwards Lifesciences in the third quarter valued at approximately $32,000. Avior Wealth Management LLC lifted its position in Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the last quarter. JFS Wealth Advisors LLC grew its stake in Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after buying an additional 166 shares in the last quarter. Finally, Roble Belko & Company Inc bought a new position in shares of Edwards Lifesciences in the 4th quarter worth $46,000. Institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 8,000 shares of company stock worth $547,430 over the last three months. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Down 1.6 %

NYSE:EW opened at $70.96 on Friday. The company has a 50-day moving average price of $72.49 and a 200-day moving average price of $69.54. The stock has a market cap of $41.85 billion, a price-to-earnings ratio of 10.24, a P/E/G ratio of 3.72 and a beta of 1.10. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12.

Analysts Set New Price Targets

A number of research firms have recently issued reports on EW. Citigroup lifted their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Piper Sandler cut their price objective on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Wolfe Research cut Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price objective on the stock. in a report on Thursday, January 16th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $70.00 target price on shares of Edwards Lifesciences in a research note on Friday, October 11th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $79.19.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.